Addex therapeutics

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

Research And Development

Publications

Dipraglurant-IR for PD-LID
Dipraglurant-ER for dystonia (BLEPHAROSPASM)
ADX71149 for epilepsy
GABAB PAM for the treatment of substance use disorder
GABAB PAM for CMT1A
mGlu7 NAM for PTSD
mGlu2 NAM for mild neurocognitive disorders
M4 PAM for Schizophrenia & Other Psychosis
mGlu4 PAM for Parkinson’s disease
mGlu3 PAM for neurodegenerative disorders

Technology platform

Allosteric Modulation

Partners & Collaborations

Industry